Does BCBS Michigan Cover Zepbound? Formulary, Exclusions, and Appeals

Blue Cross Blue Shield of Michigan does not cover Zepbound for weight loss on most commercial plans. The exclusion took effect January 1, 2025, and it also blocks Zepbound when prescribed for obstructive sleep apnea on plans that carry the exclusion. Coverage depends on your specific plan, and members have won reversals on appeal in some circumstances.

What the Formulary Says

BCBSM’s 2026 Clinical Drug List and Preferred Drug List both state that the insurer does not cover “glucagon-like peptide-agonist drugs used for weight loss, including Saxenda, Wegovy, and Zepbound for commercial members of fully insured large groups and some self-funded groups.”1Blue Cross Blue Shield of Michigan. Clinical Drug List – June 2026 Blue Care Network, the HMO affiliate, carries the same exclusion on its 2026 Custom Drug List.2Blue Cross Blue Shield of Michigan. Blue Care Network Custom Drug List 2026

Before January 1, 2025, BCBSM did cover Zepbound for weight loss, but only through strict prior authorization: age 18 or older, BMI of 35 or higher, six months of documented lifestyle modification, and enrollment in the Teladoc Health weight management program.3Blue Cross Blue Shield of Michigan. Changes to Weight Loss Drugs for Commercial Members Members were notified in mid-2024 that coverage would end at the start of 2025.4Michigan Department of Insurance and Financial Services. DIFS Order, File No. 238501-001

Which Plans Carry the Exclusion

The exclusion language reaches most, but not all, of BCBSM’s membership. Where you land depends on how your plan is structured.

  • Fully insured large group plans: Zepbound is excluded. BCBSM sets the formulary and takes the insurance risk.
  • Self-funded (ASO) employer plans: the employer decides what to cover, so some self-funded groups still include GLP-1 weight loss drugs, often with their own prior authorization criteria. If you’re not sure which category your plan falls into, ask HR.3Blue Cross Blue Shield of Michigan. Changes to Weight Loss Drugs for Commercial Members
  • MESSA plans: the Michigan Education Special Services Association, which covers many school employees, does not cover Zepbound for weight loss or for other diagnoses such as sleep apnea.5MESSA. Weight Loss Medications
  • Individual and family (ACA marketplace) plans: BCBSM sells these with their own drug lists, and the available documentation does not confirm whether the GLP-1 exclusion applies the same way. Check your plan’s drug list or call the number on your ID card.6Blue Cross Blue Shield of Michigan. Drug Lists – Individuals and Family Plans
  • Medicare Advantage: federal rules generally bar Medicare Part D and Medicare Advantage from covering anti-obesity medications. Limited coverage for Zepbound prescribed specifically for obstructive sleep apnea may exist on some plans but is not guaranteed. BCBSM’s Medicare Advantage formulary lists Mounjaro as a preferred brand for type 2 diabetes but does not list Zepbound.7Drugs.com. Does Medicare Cover Zepbound8Blue Cross Blue Shield of Michigan. Medicare Advantage Coverage Guide

What About Zepbound for Sleep Apnea

Zepbound received FDA approval in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, a second indication beyond weight management.9Eli Lilly. FDA Approves Zepbound for Obstructive Sleep Apnea Some members have tried to use the OSA indication to get around the weight-loss exclusion. BCBSM has denied those requests, and Michigan regulators have agreed.

In a June 2025 ruling, Michigan’s Department of Insurance and Financial Services upheld BCBSM’s denial of Zepbound for a member whose doctor prescribed it for OSA. The insurer told the member Zepbound “is not covered for any conditions,” and the DIFS Director ruled that because the drug list classifies Zepbound as not covered, the exclusion applies regardless of the clinical indication.10Michigan Department of Insurance and Financial Services. DIFS Order, File No. 236103-001 In an April 2025 case the denial was also upheld, though on different grounds: the independent reviewer found the clinical records did not adequately document moderate-to-severe sleep apnea.11Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234378-001

Mounjaro Is Not a Workaround

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly. The difference is the approved use: Mounjaro is for type 2 diabetes, Zepbound is for weight management and OSA. BCBSM covers Mounjaro, but only for members with a type 2 diabetes diagnosis, defined by a hemoglobin A1c of at least 6.5%.12Michigan Department of Insurance and Financial Services. DIFS Order, File No. 240509-001 Sharing an active ingredient with Zepbound is not, by itself, a route to coverage.

One December 2025 ruling carved out a narrow exception. DIFS ordered BCBSM to cover Mounjaro for a patient with polycystic ovary syndrome, citing Michigan law (MCL 500.3406q), which requires coverage of FDA-approved drugs used off-label for “chronic and seriously debilitating” conditions when peer-reviewed medical evidence supports their safety and effectiveness. An independent reviewer board-certified in endocrinology found that tirzepatide was supported by clinical guidelines for managing weight in adults with PCOS, and the Director concluded that BCBSM’s internal criteria could not override the statute.12Michigan Department of Insurance and Financial Services. DIFS Order, File No. 240509-001

When Appeals Have Worked, and When They Haven’t

DIFS has reviewed multiple BCBSM Zepbound denials under the Patient’s Right to Independent Review Act. Outcomes track closely with the specific plan language and clinical facts.

Reversals Ordered by DIFS

  • February 2025 (File 231850): the independent reviewer found BCBSM incorrectly applied a 5% weight-loss requirement while the patient was still titrating up to the maximum dose. FDA labeling does not require discontinuation during dose titration. DIFS declared Zepbound medically necessary and a covered benefit.13Michigan Department of Insurance and Financial Services. DIFS Order, File No. 231850-001
  • April 2025 (File 234012): an endocrinologist serving as reviewer found BCBSM’s criteria “not consistent with standard of care criteria” and noted that tirzepatide “can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20 percent.” DIFS ordered coverage of Zepbound 15 mg pens.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001
  • May 2025 (File 235323): the Director found that neither the plan booklet nor the drug list established Zepbound as an excluded drug for that particular member as of January 1, 2025.15Michigan Department of Insurance and Financial Services. DIFS Order, File No. 235323-001
  • June 2025 (File 235993): the reviewer again found BCBSM’s clinical criteria did not reflect current standard of care and that the patient needed adequate time for dose titration before efficacy could be assessed.16Michigan Department of Insurance and Financial Services. DIFS Order, File No. 235993-001

Denials Upheld

  • August 2025 (File 238501): the Director upheld the denial because the member’s plan explicitly excluded “lifestyle drugs (such as drugs to treat erectile dysfunction or weight loss).” The case was treated as a contractual exclusion rather than a medical necessity dispute.4Michigan Department of Insurance and Financial Services. DIFS Order, File No. 238501-001
  • November 2025 (File 240449): DIFS affirmed the denial as consistent with the plan’s exclusion of GLP-1 products used for weight loss.17Michigan Department of Insurance and Financial Services. DIFS Order, File No. 240449

The pattern is readable. Where a plan clearly excludes GLP-1 weight loss drugs or “lifestyle drugs,” appeals have failed. Where the plan language was ambiguous, or where BCBSM denied continuation of a previously authorized prescription on clinical grounds the reviewer found unsound, appeals have succeeded.

How to Appeal a Denial

Members denied coverage for Zepbound can challenge the decision in stages.

  • Internal appeal: start with BCBSM’s internal grievance process. The insurer issues a “final adverse determination” at the end of this step.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001
  • External review: within four months of the denial, request external review by submitting the denial letter, a completed external review form, and a doctor’s statement explaining why covered alternatives are ineffective and why Zepbound is medically necessary. An Independent Review Organization issues a decision within 72 hours.18Blue Cross Blue Shield of Michigan. External Drug Review
  • DIFS complaint: separately or in parallel, request review by the Michigan Department of Insurance and Financial Services under the Patient’s Right to Independent Review Act. DIFS assigns an independent medical reviewer, and the Director issues a binding order.
  • Judicial review: either party can seek review in circuit court within 60 days of the DIFS order.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001

Documentation drives results. Members who prevailed before DIFS typically submitted BMI and weight-history records, evidence of lifestyle modification (food diaries, exercise logs, app records), physician letters addressing medical necessity and comorbidities, and Teladoc Health summary reports for those enrolled in that program.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001 Before you build an appeal, pull your plan documents and look for the exact exclusion language; that language, more than anything else, tells you what kind of fight you’re in. If you cannot find it, call the customer service number on your Blue Cross ID card and ask for a written answer on your specific plan.